IMC Chicago’s Abivax ABVX Stock Holding History

IMC Chicago’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.31M	Buy	74,600 +61,100	+453%	+$7.23M	﹤0.01%	1419
2025 Q4	$1.82M	Buy	+13,500	New	+$1.47M	﹤0.01%	2507

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

IMC Chicago's ABVX Position: Q1 2026 in Review

IMC Chicago increased its Abivax (ABVX) stake by 543% in Q1 2026, buying an estimated $10.6M and bringing the position to 106,143 shares worth $11.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1152.

IMC Chicago first reported a position in ABVX in Q4 2025 and has held it in 2 quarters since. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

IMC Chicago held 106,143 shares of Abivax worth $11.8M as of Q1 2026.
IMC Chicago bought 89,624 Abivax shares in Q1 2026, an estimated $10.6M.
Abivax made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #1152 holding.
IMC Chicago first reported a position in Abivax in Q4 2025 and has held it in 2 quarters since.
254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.